News
June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...
Tarpon Springs, Florida Wednesday, June 4, 2025, 12:00 Hrs [IST] ...
TipRanks on MSN4d
Allarity Therapeutics Launches Phase 2 Trial for StenoparibAllarity Therapeutics ( ($ALLR) ) has shared an update. On June 2, 2025, Allarity Therapeutics announced the enrollment of the first patient in ...
Allarity Therapeutics, Inc. has announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to enhance their understanding of stenoparib, a dual PARP and WNT pathway ...
The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...
TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a ...
June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...
June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the“Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback